Company: TEM
Filing Date: 2025-02-25
Form Type: S-1
Source: 0001193125-25-034442
Chunk: 72

Company: Tempus AI, Inc.
Filing Date: 2025-02-25
Form: S-1
Chunk 72
---
, in a private placement to an accredited investor. |

| 6) | We also issued shares in connection with acquisitions as follows: |

| a. | in connection with our purchase of all of the outstanding shares of AKESOgen, Inc. in December 2019, we                                                                                                                           
 issued 145,466 shares of Class A common stock to former stockholders of AKESOgen, Inc. in December 2022 with a fair value of approximately $3.4 million, all of which shares were subsequently repurchased by us in January 2023. |

| b. | in connection with our acquisition of Arterys, Inc., we issued 174,499 shares of Class A common stock 
 to former stockholders of Arterys, Inc. in October 2022.                                              |

| c. | in connection with an agreement and plan of merger to acquire Mpirik Inc., we issued 130,862 shares of                                                                                                                                          
 Class A common stock to former stockholders of Mpirik Inc. in March 2023. Subsequently in March 2024, we issued 8,724 additional shares of Class A common stock to former stockholders of Mpirik Inc. pursuant to the acquisition arrangements. |

| d. | in connection with our acquisition of SEngine Precision Medicine LLC, or SEngine, we issued 142,513 shares 
 of Class A common stock to former stockholder of SEngine in October 2023.                                  |

II-2

| Subsequently in February 2024 and June 2024, we issued 429 and 19,620 additional shares, respectively, of Class A common stock to former stockholder of SEngine pursuant to the acquisition 
 arrangements.                                                                                                                                                                               |

| 7) | In December 2023, we issued a warrant to Allen & Company LLC, or Allen, an underwriter for the                                                                                                                                           
 initial public offering of our Class A common stock, or our IPO, to purchase up to 150,000 shares of our Class A common stock with an exercise price of $10 per share. In connection with the closing of our IPO in June 2024, we issued 
 109,459 shares of Class A common stock to Allen upon its net exercise of the warrant.                                                                                                                                                    |

| 8) | In November 2024, we entered into a securities purchase agreement, or the Purchase Agreement, with REALM                                                                                                                                           
 IDx, Inc., a Delaware corporation, or the Seller, and the